Alazraki, M. (2009) Pfizer Earnings Beat the Street. Beating Future Hurdles Will be Harder. Daily Finance
, 20 October, http://www.dailyfinance.com/story/investing/pfizer-earnings-beat-the-street-beating-future-hurdles-will-be/19201958/
, accessed 21 October 2009.
Angell, M. (2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.
Armstrong, W. (2009) Attack of the monster merger: What the Wyeth deal means for Pfizer – And the rest of pharma. Pharmaceutical Executive 29(3): 36–48.
Barter, P.J. et al
(2007) Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357(21): 2109–2122.CrossRef
Berenson, A. (2005) Pfizer stirs concern with plans to sell heart drugs only as a pair. New York Times, 7 March.
Berenson, A. (2006) Pfizer ends its studies on drug for heart disease. New York Times.
Biehl, J. (2007) Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly 80(4): 1083–1126.CrossRef
Chomsky, N. (2001) 9–11. New York: Seven Stories Press.
Clarke, A., Shim, J.K., Mamo, L., Fosket, J.R. and Fishman, J.R. (2003) Biomedicalization: Transformations in health, illness, and U.S. biomedicine. American Sociological Review 68(2): 161–194.CrossRef
Congressional Budget Office. (2006) A CBO study: Research and development in the pharmaceutical industry, http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf
Cooper, M. (2006) Resuscitations: Stem cells and the crisis of old age. Body and Society 12(1): 1–23.CrossRef
Cooper, M. (2008) Life As Surplus: Biotechnology and Capitalism in the Neo-Liberal Era. Seattle, WA: University of Washington Press.
Das, V. and Das, R.K. (2006) Pharmaceutical in urban ecologies: The register of the local. In: A. Petryna, A. Lakoff and A. Kleinman (eds.) Global Pharmaceuticals: Ethics, Markets, Practices. Durham, NC: Duke University Press, pp. 171–205.
Derrida, J. (1981) Plato's Pharmacy. In: Dissemination, Translated by B. Johnson. Chicago, IL: University of Chicago Press, pp. 61–171.
Dumit, J. (2002) Drugs for life. Molecular Interventions 2(3): 124–127.CrossRef
Dumit, J. (forthcoming) Drugs for Life: Managing Health and Identity through Facts and Pharmaceuticals. Durham, NC: Duke University Press.
Ecks, S. (2005) Pharmaceutical citizenship: Antidepressant marketing and the promise of demarginalization in India. Anthropology & Medicine 12(3): 239–254.CrossRef
Ecks, S. (2008) Global pharmaceutical markets and corporate citizenship: The case of Novartis’ Anti-Cancer Drug Glivec. BioSocieties 3(2): 165–181.CrossRef
Ewart, R. (2008) Lessons from Torcetrapib: Putting patient-oriented medicine first. American Family Physician 77(5, March): 597–598.
Garber, A.M. (2009) An uncertain future for cardiovascular drug development? New England Journal of Medicine 360(12, March): 1169.CrossRef
Gertner, A. (2010) Science of uncertainty: Making cases for drug incorporation in Brazil. Anthropological Quarterly 83(1): 97–112.CrossRef
Greene, J. (2008) Prescribing by Numbers: Drugs and the Definition of Disease. Baltimore, MD: Johns Hopkins University Press.
Haraway, D. (1991) A cyborg manifesto: Science, technology, and socialist-feminism in the late twentieth century. In: Simians, Cyborgs and Women: The Reinvention of Nature. New York: Routledge, pp. 149–181.
Harris, G. (2009) Pfizer pays 2.3 billion to settle marketing case. New York Times, p. B4, September.
Hayden, C. (2007) A generic solution? Pharmaceuticals and the politics of the similar in Mexico. Current Anthropology 48(4): 475–495.CrossRef
Hirschler, B. (2010) Data shows declining productivity in drug R&D. Reuters
, June, http://www.reuters.com/article/idUSTRE65Q3IM20100627
Jackson, E. (2010) Top-up payments for expensive cancer drugs: Rationing, fairness and the NHS. Modern Law Review 73(3): 399–427.CrossRef
Kahn, J. (2008) Exploiting race in drug development: BiDil's interim model of pharmacogenomics. Social Studies of Science 38(5): 737–758.CrossRef
Kahn, J. and Sankar, K. (2005) BiDil: Race medicine or race marketing? Health Affairs 24: 455–463.CrossRef
Klug, H. (2008) Law, politics, and access to essential medicines in developing countries. Politics & Society 36(2): 207–246.CrossRef
Krumholz, H.M. and Lee, T.H. (2008) Redefining quality – Implications of recent clinical trials. New England Journal of Medicine 358(24): 2537.CrossRef
Lacey, M. (2005) Look at the place!: Sudan says, “say sorry,” but the U.S. won’t. New York Times.
Lakoff, A. (2007) The right patients for the drug: Managing the placebo effect. Biosocieties 2: 57–73.CrossRef
Mamo, L. and Fishman, J.R. (2001) Potency in all the right places: Viagra as a technology of the gendered body. Body and Society 7: 13–35.CrossRef
Marres, N. and McGoey, L. (2010) Experimental failure. Presented at After Markets, Oxford University.
Martinez, B. and Goldstein, J. (2007) Big pharma faces grim prognosis: Industry fails to find new drugs to replace wonders like lipitor. Wall Street Journal,
McGoey, L. (2010) Profitable failure: Antidepressant drugs and the triumph of flawed experiments. History of the Human Sciences 23(1): 58–78.CrossRef
New York Times. (2005) A troubling drug combination. 2 March.
New York Times. (2008) Pfizer to focus on more profitable diseases. 30 September.
Nguyen, V-K. (2005) Anti-retroviral globalism, biopolitics, and therapeutic citizenship. In: A. Ong and S. Collier (eds.) Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems. Malden, MA: Blackwell, pp. 124–144.
Novas, C. (2007) Patients, profits, and values: Myozyme as an exemplar of biosociality. In: S. Gibbon and C. Novas (eds.) Biosocialities, Genetics, and the Social Sciences: Making Biologies and Identities. London: Routledge, pp. 136–156.
Persson, A. (2004) Incorporating pharmakon: HIV, medicine, and body shape change. Body and Society 10(4): 45–67.CrossRef
Petrecca, L. (2009) Pfizer offers free drugs, Lipitor, Viagra, to unemployed. USA Today, 14 May.
Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press.CrossRef
Pfizer. (2007) Pfizer announces launch of generic amlodipine besylate product by greenstone. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20070323005696&newsLang=en
, accessed 23 March.
Pfizer. (2008) Information about the MAINTAIN™ program: A free medicines program for newly unemployed Americans. http://media.pfizer.com/files/pfizer_maintain_fact_sheet.pdf
Pfizer. (2009) President Clinton, Pfizer, and Mylan announce new agreements to lower prices of medicines for patients with drug-resistant HIV in developing countries, http://mediaroom.pfizer.com/portal/site/pfizer/?ndmViewId=news_view&newsId=20090806005853&newsLang=en
Pollack, A. (2009) Forty years war: Taking big risk for big payoff, industry seeks cancer drugs. New York Times, 2 September.
Pollock, A. (2008) Pharmaceutical meaning-making beyond marketing: The racialized subjects of generic thiazide. Journal of Law, Medicine and Ethics 36(3): 530–536.CrossRef
Pollock, A. (forthcoming) Medicating Race: Heart Disease and Durable Preoccupations with Difference. Durham, NC: Duke University Press.
Rasmussen, N. (2008) On Speed: The Many Lives of Amphetamine. New York: New York University Press.
Reagan, R. (1961) Ronald Reagan Speaks Out Against Socialized Medicine, LP Record. Chicago, IL: American Medical Association.
Risen, J. (1999) To bomb Sudan Plant, or not: a year later, debates rankle. New York Times, 27 October.
Rose, N. (2006) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton, NJ: Princeton University Press.
Saul, S. (2008) In sour economy, some scale back on medications. New York Times, 30 September.
Sismondo, S. (2008) How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine Volume 66(9): 1909–1914.CrossRef
Universities Allied for Essential Medicines. (2009) Global access licensing framework. February, http://essentialmedicine.org
Wang, S.S. and Lublin, J.S. (2008) Pfizer plans to abandon heart-drug development. The Wall Street Journal, 30 September.
Van, Der Geest S., White, S.R. and Hardon, A. (1996) The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology 25: 153–178.CrossRef
Zizek, S. (2009) First as Tragedy, Then as Farce. London and Brooklyn, NY: Verso Books.